Clinical Response and Pattern of B cell Suppression with Single Low Dose Rituximab in Nephrology

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Lack of established rituximab dosing guidelines in nephrology.
• Current dosing often extrapolated from lymphoproliferative disorder treatments.
• No clear targets for CD19 B cell levels for rituximab administration.

Purpose of the Study:

• To evaluate the efficacy of a low-dose rituximab regimen in nephrology patients.
• To assess the impact of rituximab on CD19 B cell depletion and clinical outcomes.
• To explore rituximab's role in steroid-dependent nephrotic syndrome (SDNS), frequently relapsing nephrotic syndrome (FRNS), and membranous nephropathy (MN).

Main Methods:

• Administered 100 mg rituximab to 42 adult patients with SDNS, FRNS, MN, or high-risk kidney transplants.
• Monitored CD19 B cell counts and clinical status at multiple time points up to 1 year.
• Adjusted subsequent rituximab doses based on CD19 B cell reconstitution and clinical response.

Main Results:

• Significant reduction in CD19 B cell percentage observed at 30, 90, and 180 days post-treatment (P≤0.001).
• 95.2% of patients achieved CD19 B cell suppression below 1% at 30 days.
• High remission rates (96.7% at day 30, 70% at 1 year) in SDNS/FRNS patients, with reduced steroid requirements.
• CD19 B cell percentage at 90 days correlated with relapse risk (OR 1.42, P=0.001).

Conclusions:

• Low-dose rituximab effectively depletes CD19 B cells for up to 90 days.
• Sustained remission achieved in a majority of SDNS/FRNS patients.
• Further investigation is warranted for rituximab's efficacy in preventing relapses and managing MN and transplant rejection.